Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) response to corticosteroids and cytotoxic medications appears to be the most important determinant of survival. The purpose of this retrospective study was to analyse the determinants of response to immunosuppressive therapy with prednisone alone, or prednisone and cyclophosphamide, in IPF. Twenty five consecutive patients were studied. Initial evaluation in untreated patients included clinical, biological and functional parameters. Sequential evaluation by pulmonary function tests (forced vital capacity (FVC) and transfer factor of the lungs for carbon monoxide (TLCO)) was performed at a 3 month interval. Response to therapy was defined as an improvement in FVC and/or TLCO of more than 10% after 12 months, with maintenance of this improvement for at least another 12 months. Twelve of the 25 patients were classified as responders. A symptomatic disease of less than 12 months duration before onset of therapy related to response. FVC was more impaired in the group of responders when the comparison was limited to patients with an FVC of less than 90%. Bronchoalveolar lavage cell counts were not significantly different between responders and non-responders. Assessment of pulmonary function after 3 months of treatment was predictive of maintenance of the response or of even further improvement. Patients with improved FVC after 3 months of therapy had a significantly shorter symptomatic disease before onset of treatment (7.6 +/- 7.1 vs 20.2 +/- 18.6 months). A beneficial effect of addition of cyclophosphamide was observed only in patients who demonstrated an early but short-lived improvement to steroids. Adverse reactions of immunosuppressive therapy were noticed in 10 patients, and required discontinuation of treatment in six of them.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  R. D. du Bois,et al.  Prediction of disease progression in idiopathic pulmonary fibrosis. , 1994, The European respiratory journal.

[2]  J. Roca,et al.  Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. , 1994, The European respiratory journal.

[3]  C. Vesin,et al.  Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. , 1994, The European respiratory journal.

[4]  D. Schwartz,et al.  Determinants of progression in idiopathic pulmonary fibrosis. , 1994, American journal of respiratory and critical care medicine.

[5]  J. McDougall,et al.  Colchicine in the treatment of pulmonary fibrosis. , 1993, Chest.

[6]  D. Schwartz,et al.  Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. , 1993, Chest.

[7]  J. Roca,et al.  Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up. , 1992, Thorax.

[8]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.

[9]  T. King,et al.  Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. , 1990, The American journal of medicine.

[10]  B. Wallaert,et al.  Superoxide anion generation by alveolar inflammatory cells in simple pneumoconiosis and in progressive massive fibrosis of nonsmoking coal workers. , 1990, The American review of respiratory disease.

[11]  J. Darbyshire,et al.  Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. , 1989, Thorax.

[12]  J. Cordier,et al.  Gallium-67 scanning in the staging of cryptogenetic fibrosing alveolitis and hypersensitivity pneumonitis. , 1988, The European respiratory journal.

[13]  G. Hunninghake,et al.  Prognostic role of eosinophils in pulmonary fibrosis. , 1987, Chest.

[14]  M. Schwarz,et al.  Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. , 1987, The American review of respiratory disease.

[15]  M. Turner-Warwick,et al.  The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. , 1987, The American review of respiratory disease.

[16]  A. Degraff,et al.  Adverse effects of cyclophosphamide in idiopathic pulmonary fibrosis. , 1985, Connecticut medicine.

[17]  E. Taskinen,et al.  Prognosis of cryptogenic fibrosing alveolitis. , 1983, Thorax.

[18]  R. Rudd,et al.  Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. , 1981, The American review of respiratory disease.

[19]  A. Salsbury,et al.  Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. , 1980, Thorax.

[20]  B. Burrows,et al.  Cryptogenic fibrosing alveolitis: clinical features and their influence on survival , 1980, Thorax.

[21]  J. Allen,et al.  Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. , 1978, The American journal of medicine.

[22]  R G Gupta,et al.  Natural history and treated course of usual and desquamative interstitial pneumonia. , 1978, The New England journal of medicine.

[23]  W. Roberts,et al.  Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. , 1976, Annals of internal medicine.

[24]  H. Kazemi,et al.  Interstitial lung disease resistant to corticosteroid therapy. Report of three cases treated with azathioprine or cyclophosphamide. , 1975, Chest.